Erythropoietin protects against ischaemic acute renal injury

Nephrology Dialysis Transplantation

Volumn 19, Issue 2, 2004, Pages 348-355

  Vesey, David A ^a   Cheung, Catherine ^a   Pat, Betty ^a   Endre, Zoltan ^a   Gobé, Glenda ^a   Johnson, David W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acute; Apoptosis; Hypoxia; Kidney failure; Kidney tubular necrosis; Kidney tubules; Mitosis; Regeneration

Indexed keywords

CREATININE; CYCLINE; DNA; LACTATE DEHYDROGENASE; RECOMBINANT ERYTHROPOIETIN; THYMIDINE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL REGENERATION; CELL VIABILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA SYNTHESIS; DRUG MECHANISM; FREQUENCY ANALYSIS; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; KIDNEY STRUCTURE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; APOPTOSIS; BIOPSY, NEEDLE; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION TESTS; KIDNEY TUBULAR NECROSIS, ACUTE; KIDNEY TUBULES, PROXIMAL; MALE; PROBABILITY; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; REGENERATION;

EID: 1042292029     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg547     Document Type: Article

References (35)

1. Briganti E, McNeil J, Atkins R, Knight J. The Australian Kidney: National Epidemiological Survey of Diseases of the Kidney and Urinary Tract. The Australian Kidney Foundation, Adelaide; 1999
2. Hirschberg R, Kopple J, Lipsett P et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999; 55: 2423-2432
3. Schena FP. Role of growth factors in acute renal failure. Kidney Int Suppl 1998; 66: S11-S15
4. Power DA, Duggan J, Brady HR. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Clin Exp Pharmacol Physiol Suppl 1999; 26: S23-S28
5. Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785-792
6. Gobe G, Buttyan R. Apoptosis in the pathogenesis of renal disease with a focus on tubulointerstitial injury. Nephrology 2003; 7: 287-293
7. Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640
8. Siren AL, Fratelli M, Brines M et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98: 4044-4049
9. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-10531
10. Calapai G, Marciano MC, Corica, F et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000; 401: 349-356
11. Bernaudin M, Marti HH, Roussel S et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999; 19: 643-651
12. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820
13. Bagnis C, Beaufils H, Jacquiaud C et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001; 16: 932-938
14. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266: F360-F366
15. Liano F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 1996; 50: 811-818
16. Johnson DW, Brew BK, Poronnik P et al. Transport characteristics of human proximal tubule cells in primary culture. Nephrology 1997; 3: 183-194
17. Johnson DW, Saunders HJ, Baxter RC, Field MJ, Pollock CA. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int 1998; 54: 747-757
18. Walker NI, Harmon BV, Gobe GC, Kerr JF. Patterns of cell death. Methods Achiev Exp Pathol 1988; 13: 18-54
19. Gobe G, Zhang XJ, Willgoss DA et al. Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol 2000; 11: 454-467
20. Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993; 170: 1-8
21. Johnson DW, Saunders HJ, Brew BK et al. Human renal fibroblasts regulate proximal tubule cell growth and transport via the IGF-I axis. Kidney Int 1997; 52: 1486-1496
22. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001; 59: 246-251
23. Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ. Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia. Kidney Int 1993; 44: 430-435
24. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982
25. Okada A, Kinoshita Y, Maekawa T et al. Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells. Digestion 1996; 57: 328-332
26. Ogilvie M, Yu X, Nicolas-Metral V et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 2000; 275: 39754-39761
27. Mioni R, Gottardello F, Bordon P, Montini G, Foresta C. Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells. Acta Endocrinol (Copenh) 1992; 127: 459-465
28. Ammarguellat F, Gogusev J, Drueke TB. Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 1996; 11: 687-692
29. Yasuda Y, Musha T, Tanaka H et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001; 84: 836-843
30. Sinor AD, Greenberg DA. Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity. Neurosci Lett 2000; 290: 213-215
31. Cerami A. Beyond erythropoiesis: novel applications for recombinant human erythropoietin. Semin Hematol 2001; 38: 33-39
32. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 2001; 412: 641-647
33. Gregory T, Yu C, Ma A et al. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 1999; 94: 87-96
34. Silva M, Benito A, Sanz C et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999; 274: 22165-22169
35. Kusano E, Akimoto T, Inoue M et al. Human recombinant erythropoietin inhibits interleukin-1β-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 1999; 14: 597-603